[HTML][HTML] Regulation of PD-L1: a novel role of pro-survival signalling in cancer

J Chen, CC Jiang, L Jin, XD Zhang - Annals of oncology, 2016 - Elsevier
Evasion of immune system is a hallmark of cancer, which enables cancer cells to escape the
attack from immune cells. Cancer cells can express many immune inhibitory signalling …

Targeting EphA2 in cancer

T Xiao, Y Xiao, W Wang, YY Tang, Z Xiao… - Journal of hematology & …, 2020 - Springer
Eph receptors and the corresponding Eph receptor-interacting (ephrin) ligands jointly
constitute a critical cell signaling network that has multiple functions. The tyrosine kinase …

Chimeric antigen receptors modified T-cells for cancer therapy

H Dai, Y Wang, X Lu, W Han - Journal of the National Cancer …, 2016 - academic.oup.com
The genetic modification and characterization of T-cells with chimeric antigen receptors
(CARs) allow functionally distinct T-cell subsets to recognize specific tumor cells. The …

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

G Dagar, A Gupta, T Masoodi, S Nisar, M Merhi… - Journal of translational …, 2023 - Springer
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Principles and current clinical landscape of multispecific antibodies against cancer

M Elshiaty, H Schindler, P Christopoulos - International journal of …, 2021 - mdpi.com
Building upon the resounding therapeutic success of monoclonal antibodies, and supported
by accelerating progress in engineering methods, the field of multispecific therapeutic …

[HTML][HTML] Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1

S Jutz, J Leitner, K Schmetterer, I Doel-Perez… - Journal of …, 2016 - Elsevier
Engagement of the T cell receptor complex reprograms T cells for proliferation, cytokine
production and differentiation towards effector cells. This process depends on activating …

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD

A Künkele, AJ Johnson, LS Rolczynski… - Cancer immunology …, 2015 - AACR
Chimeric antigen receptor (CAR) development is biased toward selecting constructs that
elicit the highest magnitude of T-cell functional outputs. Here, we show that components of …

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia

J Wang, S Chen, W Xiao, W Li, L Wang, S Yang… - Journal of hematology & …, 2018 - Springer
Background Acute myeloid leukemia (AML) is one of the most common types of adult acute
leukemia. Standard chemotherapies can induce complete remission in selected patients; …

Emerging CAR T cell strategies for the treatment of AML

P Vishwasrao, G Li, JC Boucher, DL Smith, SK Hui - Cancers, 2022 - mdpi.com
Simple Summary Chimeric antigen receptors (CARs) targeting CD19 have emerged as a
new treatment for hematological malignancies. As a “living therapy”, CARs can precisely …

Current advances in T-cell-based cancer immunotherapy

M Wang, B Yin, HY Wang, RF Wang - Immunotherapy, 2014 - Future Medicine
Cancer is a leading cause of death worldwide; due to the lack of ideal cancer biomarkers for
early detection or diagnosis, most patients present with late-stage disease at the time of …